Never Too Old: Medication Improves Survival Rates After a First Heart Attack Even in Patients Over 90 Years Old

Researchers have found that prescribing guideline-directed medical treatment (GDMT), regardless of the number of medications, can improve survival rates in patients 90 years of age and older following their first heart attack, with the greatest benefit observed in patients who received all four recommended post-acute myocardial infarction (AMI) therapies. These include beta-blockers, antiplatelets, lipid-lowering drugs, and renin-angiotensin-aldosterone system inhibitors. The findings of the article opens in new tab/window appearing in the Canadian Journal of Cardiology opens in new tab/window, published by Elsevier, can guide future clinical approaches to managing first-onset AMI in nonagenarians and centenarians.

Life expectancy has been steadily increasing over time. In 2021, there were more than 861,000 Canadians who were aged 85 and older, an age group that is rapidly increasing in developed countries around the world. Since age is an independent risk factor for developing cardiovascular disease, there is a growing need for guidance in the management of this elderly population.

The lead investigator of the article "Guideline-directed Medical Therapy in Nonagenarians and Centenarians (≥ 90 Years Old) After First-onset Myocardial Infarction—a National Registry Study opens in new tab/window," Ching-Hui Sia, MBBS, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, and Department of Cardiology, National University Heart Centre Singapore, says, "As clinicians, we are often hesitant to prescribe GDMT for nonagenarians and centenarians presenting with AMI. This reluctance is driven by concerns over polypharmacy, high comorbidity burden, frailty, and the risk of adverse drug reactions, such as postural hypotension, which can lead to falls. We sought to clarify, in real-world clinical practice, whether prescribing more medications to this age group might actually be associated with worse survival outcomes."

The researchers conducted a retrospective cohort study using Singapore’s National Myocardial Infarction Registry, including 3,264 patients aged 90 years and above who experienced a non-ST elevation myocardial infarction between 2007 and 2020. They compared survival among groups stratified by the number of GDMTs prescribed at discharge (0, 1–2, 3, or 4). The analysis demonstrated that prescribing any number of GDMTs was associated with improved survival, with the greatest benefit observed in patients who received all four recommended therapies.

This is the largest study to date evaluating post-myocardial infarction (MI) outcomes in patients aged 90 and above using data from a national registry in a high-performing, well-resourced healthcare system. The timely and important findings offer real-world evidence that can help inform more confident prescribing practices for very elderly patients.

Coauthor of the accompanying editorial "Medical Management for Patients 90 Years Old and Up After Acute Coronary Syndrome—Never Too Old opens in new tab/window," Karen B. Ho, MD, Division or Cardiology, Department of Medicine, Mazankowski Heart Institute, Edmonton, notes, "Despite the significant attention given to the adverse effects of polypharmacy, underprescription in the elderly is an increasingly recognized and important problem. The appropriate acute coronary syndrome (ACS) management in this age group is challenging owing to a lack of evidence and concerns regarding the tolerability and safety of medications. The current study encouragingly suggests that GDMT after ACS is associated with improved survival in this very advanced age group, and the more complete the therapy, the better. Therefore, in the absence of contraindications, clinicians should not withhold GDMT on the basis of age alone."

The editorial’s coauthor Michelle M. Graham, MD, Division or Cardiology, Department of Medicine, Mazankowski Heart Institute, Edmonton, adds, "At the heart of the discussion is to consider what older adults value. In this study, the primary outcome was all-cause mortality. However, for patients of very advanced age, quality of life may be as or more important as their quantity of life. Avoiding repeat emergency room visits and rehospitalizations and maintaining independence may be bigger priorities. It is important to consider how additional medications can help elderly patients achieve their goals of care. Future research on the management of cardiovascular disease in older adults should emphasize the effects of guideline-directed medical therapy on patient-important outcomes, such as functional and cognitive capacity and days out of hospital."

Dr. Sia concludes, "Our findings suggest that physicians should carefully assess any decision to not manage a patient aggressively with GDMT unless there is a well-founded reason. Advanced age alone does not appear to be an adequate reason to withhold the prescription of GDMTs. Of course, the benefits of GDMTs must always be weighed against the potential risks when prescribing them to nonagenarians and centenarians in order to achieve the best therapeutic outcomes."

Notes for editors

The article is “Guideline-directed Medical Therapy in Nonagenarians and Centenarians (≥ 90 Years Old) After First-onset Myocardial Infarction—a National Registry Study,” by Hon Jen Wong, MBBS, Keith Zhi Xian Toh, MBBS, Chen Ee Low, MBBS, Chun En Yau, MBBS, Yao Hao Teo, MBBS, Yao Neng Teo, MBBS, Vanda W.T. Ho, MB BChir, Li Feng Tan, MBBS, Ping Chai, MBBS, Poay Huan Loh, MB BCh, James W.L. Yip, MBBS, Andrew Fu-Wah Ho, MBBS, PhD, David Foo, MBBS, Pow-Li Chia, MBBS, Patrick Zhan-Yun Lim, MBBS, Khung Keong Yeo, MBBS, Weien Chow, MBBS, Daniel Thuan Tee Chong, MBBS, Derek J. Hausenloy, MBBS, PhD, Mark Y.Y. Chan, MBBS, PhD, and Ching-Hui Sia, MBBS (https://doi.org/10.1016/j.cjca.2025.01.031 opens in new tab/window).

The article is openly available for 30 days at https://onlinecjc.ca/article/S0828-282X(25)00101-1/fulltext opens in new tab/window.

Journalists wishing to speak to the authors should contact Ching-Hui Sia, MBBS, at [email protected] opens in new tab/window.

This study was supported by the CArdiovascular DiseasE National Collaborative Enterprise (CADENCE) National Clinical Translational Program (MOH-001277-01). Ching-Hui Sia was supported by the Singapore Ministry of Health National Medical Research Council’s Clinician Scientist Individual Research Grant New Investigator Grant (MOH-001080-00) and Transition Award (MOH-001368-00).

The editorial is "Medical Management for Patients 90 Years Old and Up After Acute Coronary Syndrome—Never Too Old," by Karen B. Ho, MD, and Michelle M. Graham, MD (https://doi.org/10.1016/j.cjca.2025.03.013 opens in new tab/window).

The article is openly available for 30 days at https://onlinecjc.ca/article/S0828-282X(25)00197-7/fulltext opens in new tab/window.

Journalists wishing to speak to the authors should contact Karen B. Ho, MD, at [email protected] opens in new tab/window.

Both articles appear online in the Canadian Journal of Cardiology, published by Elsevier.

Full text of the articles is also available to credentialed journalists upon request. Contact Astrid Engelen at +31 6 14395474 or [email protected] opens in new tab/window to request a PDF of the article or more information.

About the Canadian Journal of Cardiology

The Canadian Journal of Cardiology opens in new tab/window is the official journal of the Canadian Cardiovascular Society opens in new tab/window. It is a vehicle for the international dissemination of new knowledge in cardiology and cardiovascular science, particularly serving as a major venue for the results of Canadian cardiovascular research and Society guidelines. The journal publishes original reports of clinical and basic research relevant to cardiovascular medicine as well as editorials, review articles, case reports, and papers on health outcomes, policy research, ethics, medical history, and political issues affecting practice. www.onlinecjc.ca opens in new tab/window

About the Editor-in-Chief

Editor-in-Chief Stanley Nattel, MD, is Paul-David Chair in Cardiovascular Electrophysiology and Professor of Medicine at the University of Montreal and Director of the Electrophysiology Research Program at the Montreal Heart Institute Research Center.

About the Canadian Cardiovascular Society (CCS)

The CCS opens in new tab/window is the national voice for cardiovascular clinicians and scientists, representing more than 2,300 cardiologists, cardiac surgeons and other heart health specialists across Canada. We advance heart health for all by setting standards for excellence in heart health and care, building the knowledge and expertise of the heart team, and influencing policy and advocating for the heart health of all Canadians. For further information on the CCS visit www.ccs.ca/en opens in new tab/window.

About Elsevier

A global leader in advanced information and decision support, Elsevier helps to advance science and healthcare, to advance human progress. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,700 employees around the world, including 2,300 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 3,000 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy. Together with the Elsevier Foundation opens in new tab/window, we work in partnership with the communities we serve to advance inclusion in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX opens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.